A b s t r a c t
Drug-induced immune hemolytic anemia (IHA) occurs rarely, with an estimated incidence of about 1 case per million of the population. 1 In the 1970s, 67% of drug-induced IHA was due to methyldopa and 23% to penicillin. 2 Since the late 1980s, 88% of drug-induced IHA that our laboratory has studied has been due to the second-and third-generation cephalosporins, cefotetan (75%) and ceftriaxone (13%). 3, 4 ❚Table 1❚ shows that first-generation cephalosporins rarely caused IHA. The clinical and serologic manifestations in these cases were similar to penicillin-induced IHA. 2 In contrast, 3 second-generation cephalosporins and 4 thirdgeneration cephalosporins have been associated with numerous cases of IHA (Table 1) . In some cases, severe intravascular hemolysis occurred, which was supported by serologic findings that indicated an "immune complex" mechanism (the patient's serum reacts with untreated RBCs in the presence of drug) rather than the "drug adsorption" mechanism (the patient's serum reacts with drug-coated RBCs). Fatal hemolysis occurred in 1 (33%) of 3 cases due to cefoxitin, 11 (17%) of 64 cases due to cefotetan, and 9 (47%) of 19 cases due to ceftriaxone.
The extent of cross-reactivity of cefotetan and ceftriaxone antibodies with RBCs in the presence of other cephalosporins and penicillin is poorly documented. In a few reports, the patient's serum samples containing cefotetan (n = 9) or ceftriaxone (n = 3) antibodies were tested by the drug adsorption or immune complex methods against 1, 7,10,24 2, 8, 12, 25, 26 3, 27 4, 28 or 5 18 different antibiotics. We present results of testing 7 cefotetan antibody samples and 1 ceftriaxone antibody sample against 9 other cephalosporins, penicillin, and 7-aminocephalosporanic acid, the basis for semisynthetic cephalosporins. prepared in a 0.1-mol/L concentration of sodium barbital (Sigma) buffer, pH 9.8, or phosphate-buffered saline (PBS), pH 7.3, respectively. Group O RBCs were added, incubated for 1 to 2 hours at room temperature (penicillin) or 37°C (cephalosporins), washed, and suspended to 3% to 5% (vol/vol) in PBS for use.
Ceftriaxone has never been shown to bond to RBCs by the aforementioned methods. 4 A previously described method using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Sigma) was used 31, 32 to try to bond ceftriaxone to RBCs. Briefly, 3 mL of ceftriaxone (6.7 mg/mL PBS), 0.1 mL 50% washed type O RBCs, and 1 mL freshly prepared carbodiimide (50 mg/mL in PBS) were incubated for 50 minutes at 4°C and then poured into 4°C PBS + 2% Na 4 EDTA (Sigma). Treated RBCs were washed 3 times and resuspended to 3% to 5% (vol/vol) for use.
Six serum or plasma samples containing cefotetan (historic antiglobulin test titers ranged from 65,000 to 262,000) antibodies and a pool of normal "inert" plasma were tested, undiluted and/or diluted in PBS, against drugtreated and untreated RBCs by a saline (60 minutes at 37°C) anti-IgG (American National Red Cross, Washington, DC) method. The normal plasma was used as a control for nonspecific reactions with cephalosporin-treated RBCs. 1, 33 Antibody Detection Using "Immune Complex" Method Three serum samples that historically reacted to titers of 1,024 to 4,096 (antiglobulin test) when tested against untreated RBCs in the presence of cefotetan and 1 serum sample that reacted in the presence of ceftriaxone to titers of 80, 5,120, and 640 (hemolysis, agglutination, antiglobulin test, respectively) were used for testing in the presence of other drugs by a previously described method. 2 Two 3 Arndt et al, 4 Badon et al, 6 Johnson et al, 7 Stroncek et al, 8 Naylor et al, 9 Moes and MacPherson, 10 Marques et al, 11 Ray et al, 12 Chai et al 13 3 Arndt et al, 4 Longo et al, 14 Maraspin et al, 15 Meyer et al, 16 Viner et al, 17 Seltsam and Salama, 18 21 Endoh et al, 22 Calhoun et al 23 AA, autoantibody (serum reacts with RBCs without addition of drug); DC, serum reacts with drug-coated RBCs; IC, "immune complex" (serum reacts in presence of drug + uncoated RBCs). * Serum samples from patients with immune hemolytic anemia due to the first-generation cephalosporins and cefamandole were not tested by the immune complex method. © American Society for Clinical Pathology volumes of serum, 2 volumes of complement source, 2 volumes of drug solution (1 mg/mL in PBS), and 1 volume of 10% ficin-treated RBCs were incubated for 1 hour at 37°C. After examination for hemolysis, agglutination, or both, the RBCs were washed and tested with polyspecific antiglobulin serum (Ortho Diagnostic Systems, Raritan, NJ). Doubling dilutions of the 3 cefotetan antibody serum samples (in complement source) were tested in the presence of cefotetan to determine the hemolysin and antiglobulin test titers vs ficin-treated RBCs.
Hapten-Inhibition Studies
Two samples containing cefotetan antibodies were tested, at a dilution predetermined to react 2+ by antiglobulin test against cefotetan-treated RBCs, in the presence of different concentrations of drug by a modification of previously described hapten-inhibition methods. 32, 34 One volume of the cefotetan antibody dilution (1 in 20,000 in PBS) was incubated with 1 volume of drug (0.1, 1.0, and 10.0 mg/mL in PBS) for 1 hour at 37°C. One volume of 3% to 5% (vol/vol) cefotetan-treated RBCs was added, and the tests were reincubated for 1 hour at 37°C. After examination for agglutination, the RBCs were washed and tested with anti-IgG.
Results

Drug-Treated RBCs
Results are shown in ❚Table 2❚. All 6 serum samples containing cefotetan antibodies showed reactivity with cephalothin-and cefoxitin-treated RBCs. Most samples containing cefotetan antibodies showed some weak reactivity with penicillin-treated RBCs. Weak reactivity was seen, using some serum samples, with some of the other drugtreated RBCs.
Immune-Complex Testing
Results are shown in ❚Table 3❚. The 3 samples of cefotetan antibodies did not show hemolysis in the presence of any drug other than cefotetan. Only 1 sample containing cefotetan antibodies (sample 2) showed reactivity in the antiglobulin test in the presence of a drug other than cefotetan; this was cephalothin. The serum containing ceftriaxone antibodies hemolyzed enzyme-treated RBCs only in the presence of 1 drug other than ceftriaxone; this was cefotaxime. Weak agglutination and/or positive antiglobulin test results were seen in the presence of cefotaxime, cefamandole, and cefoperazone. A pool of fresh normal serum samples, tested in parallel, was nonreactive.
Hapten Inhibition
Results are shown in ❚Table 4❚. Both samples of cefotetan antibodies were inhibited or partially inhibited by 10-mg/mL solutions of cefotetan and cephalothin; 1 was additionally inhibited by a 10-mg/mL solution of ceftazidime.
Discussion
Second-and third-generation cephalosporins are, by far, the most common cause of drug-induced IHA at present. 3, 4 We often are asked what would be the effect of giving other cephalosporins to patients who have (or previously had) druginduced IHA due to cefotetan or ceftriaxone antibodies. We could find few data in the literature on the degree of crossreactivity of various cephalosporins. The same question also was posed some years ago regarding the various penicillins and the cross-reactivity of antibodies to penicillin with the first-generation cephalosporins (eg, cephalothin). Most of the work relating to the latter question involved allergic reactions (eg, Could patients who were allergic to penicillin G receive other penicillins, or cephalothin?). [35] [36] [37] [38] [39] [40] Penicillins and cephalosporins share a basic beta-lactam structure ❚Figure 1❚. Antibodies can be directed to this basic structure or to side chains, which may be specific to a certain antibiotic. Most penicillin-sensitive patients develop antibodies to the beta-lactam nucleus; thus, extensive cross-reactions are observed with semisynthetic penicillins that have different side chains. 43 Some patients develop antibodies exclusively against side chains (eg, a patient may be allergic to amoxicillin but not to penicillin G).
Cross-reactivity of penicillins and cephalosporins has been more controversial. Although there is evidence that antibody responses to penicillins and cephalosporins are closely linked, 44 the incidence of reactions to cephalosporins in patients with a history of penicillin allergy is low. Novalbos et al 40 reported that the risk of a patient with penicillin allergy having an allergic reaction to cephalosporins was very low if the cephalosporins had a side chain different from the responsible penicillin. Cephalosporin allergy in patients not allergic to penicillin has been reported, but the exact incidence is unclear. 45 Cerny and Pichler 45 believe that the interpretation of available data is controversial, and, although some believe it is safe to administer a cephalosporin to a patient with penicillin allergy, they still recommend an immunologically unrelated antibiotic for patients with penicillin or cephalosporin allergy. 2+  2+  2½+  2+  2+  2+  Cefamandole  2+  3+  2+  2+  2+  2+  Cefazolin  2+  2½+  2+  2+  2+  2+  Cefepime  2+  2+  2+  2+  2+  2+  Cefoperazone  2+  2+  2+  2+  2+  2+  Cefotaxime  2+  2+  2+  2+  2+  2+  Cefoxitin  2+  2+  2+  2+  2+  2+  Ceftazidime  2+  2+  M+  2+  2+  2+  Ceftriaxone  2+  2+  2+  2+  2+  2+  Cephalothin  2+  2+  ½+  2+  2+  1+  Penicillin  2½+  2+  2+  2+  2+ There are some data in the literature relating to crossreactivity of penicillin and various cephalosporin antibodies with respect to RBC interactions. Abraham et al 34 described a severe cutaneous reaction to cephalothin in a patient who previously had received penicillin repeatedly. The patient had a positive skin test with cephalothin but not with penicillin. The patient also had an antibody that reacted with cephalothin but not with penicillin-treated RBCs. The patient subsequently was given penicillin with no reaction. Petz 46 showed that penicillin and cephalothin antibodies usually cross-react with penicillin and cephalothin-treated RBCs, but in 40% of serum samples, strikingly dissimilar titers are present. When penicillin was administered to patients with antibodies to both types of treated RBCs, 55% showed an increased titer with penicillin-treated RBCs and 23% an increased titer with cephalothin-treated RBCs. Following cephalothin administration, 25% showed increased titers against cephalothin-treated RBCs and 14% with penicillintreated RBCs. Spath et al 47 showed that serum samples from patients in whom positive direct antiglobulin tests developed following cephalothin administration reacted with penicillin and cephalothin-treated RBCs to a similar titer. Adsorption of 3 serum samples with penicillin-treated RBCs caused an almost complete loss of activity, a moderate loss of activity, and no significant decrease in titer, respectively, against cephalothin-treated RBCs.
The published reports of immune hemolytic anemia caused by cefotetan contain some reports of the cefotetan antibodies' being tested against RBCs treated with other cephalosporins and sometimes penicillin ❚Table 5❚. One reported negative reactions with cefotaxime-coated RBCs, 27 and 3 reported negative reactions with cefazolin. 10, 12, 27 There are single reports of positive reactions with cefadroxil, 26 cephalexin, 8 ceftriaxone, 7 and cephalothin. 25 Two reported positive 26, 27 and 2 reported negative 12, 25 reactions with penicillin-treated RBCs.
Compared with the other cephalosporins shown in Figure  1 , cefotetan has a unique R 1 group. The portion(s) of the cefotetan molecule against which the patient's antibodies are directed is unknown. Both cephalothin and cefoxitin showed the strongest cross-reactivity with cefotetan antibodies. Their R 1 and R 2 groups are very similar to each other but are quite different from those in cefotetan. Cefamandole, which has the same R 2 structure as cefotetan, was only weakly crossreactive in our studies. Cefamandole, cefoperazone, and ❚Figure 1❚ Chemical structures for 7-aminocephalosporanic acid (7-ACA), penicillin, the cephalosporin (eg, cephem) nucleus, and the R 1 and R 2 side chains found in the cephalosporins that were tested in the present study (modified from Mandell and Petri 41 and O'Neil 42 ). 
Conclusions
There are data in the literature proving that patients have a more severe hemolytic anemia (even fatal hemolytic anemia) when receiving a second dose of the drug causing the original hemolytic episode. It is not always clear whether drugs that are closely related will cause the same clinical effects. Although it usually is recommended that patients with cephalosporin-induced hemolytic anemia never take any of the cephalosporins again, there are few data to support that advice. Our results suggest that there is very little cross-reactivity with antibodies to the 2 most common cephalosporins (cefotetan and ceftriaxone) to cause druginduced IHA and the other cephalosporins we tested. Whether these in vitro data relate to in vivo reactivity remains unknown.
